Tiziana Life Sciences (TLSA) News Today $1.49 -0.04 (-2.61%) Closing price 04:00 PM EasternExtended Trading$1.50 +0.01 (+0.34%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Tiziana Life Sciences (NASDAQ:TLSA) Trading 5.8% Higher - Time to Buy?June 17, 2025 | marketbeat.comTiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis TargetingJune 13, 2025 | seekingalpha.comTiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosingJune 13, 2025 | proactiveinvestors.comTiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis CenterJune 13, 2025 | globenewswire.comTiziana Life Sciences to Present at the Bio International ConventionJune 13, 2025 | globenewswire.comTiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% - Still a Buy?May 28, 2025 | marketbeat.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s DiseaseMay 23, 2025 | finance.yahoo.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's DiseaseMay 23, 2025 | globenewswire.comJournal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's DiseaseMay 15, 2025 | finance.yahoo.comTiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study showsMay 15, 2025 | proactiveinvestors.comTiziana Life Sciences reports purchase of shares by chairmanMay 12, 2025 | msn.comTiziana Life Sciences Announces Purchase of Shares by ChairmanMay 12, 2025 | globenewswire.comTiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumabMay 9, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal ForalumabMay 9, 2025 | globenewswire.comTiziana shares surge 21% on promising multiple sclerosis dataMay 6, 2025 | proactiveinvestors.comTiziana reports encouraging results for nasal MS drug in early studyMay 6, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple SclerosisMay 6, 2025 | globenewswire.comTiziana Life Sciences (NASDAQ:TLSA) Shares Up 5.6% - Here's What HappenedApril 23, 2025 | marketbeat.comTiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of MassachusettsApril 23, 2025 | proactiveinvestors.comTiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis TrialApril 23, 2025 | globenewswire.comTiziana Life announces dosing at JHU, part of Phase 2 trial of foralumabApril 3, 2025 | markets.businessinsider.comTiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns HopkinsApril 2, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical TrialApril 2, 2025 | globenewswire.comShort Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Rises By 42.5%March 31, 2025 | marketbeat.comTiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMSMarch 25, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis TrialMarch 25, 2025 | globenewswire.comTiziana Life Sciences to Present at the 37th Annual Roth ConferenceMarch 17, 2025 | globenewswire.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Down 39.2% in FebruaryMarch 16, 2025 | marketbeat.comTiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price RuleMarch 14, 2025 | globenewswire.comTiziana: Foralumab Drug Development Presses On With Additional EAP EnrollmentMarch 5, 2025 | seekingalpha.comTiziana submits FDA investigational new drug applicationMarch 4, 2025 | proactiveinvestors.comTiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical TrialMarch 4, 2025 | globenewswire.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short InterestMarch 4, 2025 | marketbeat.comTiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study revealsFebruary 27, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain InjuryFebruary 27, 2025 | globenewswire.comTiziana Life Sciences expects to complete Long Covid study in Q2February 25, 2025 | markets.businessinsider.comTiziana Life Sciences nearing completion of long COVID study on foralumabFebruary 25, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Long Covid Study to Complete in Second QuarterFebruary 25, 2025 | globenewswire.comTiziana Life Sciences advances foralumab towards commercialization with key manufacturing partnershipFebruary 21, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLCFebruary 21, 2025 | globenewswire.comTiziana Life Sciences doses additional four patients in multiple sclerosis trialFebruary 18, 2025 | markets.businessinsider.comTiziana Life Sciences announces dosing of additional patients in MS Expanded Access ProgramFebruary 18, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access ProgramFebruary 18, 2025 | globenewswire.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short InterestFebruary 13, 2025 | marketbeat.comTiziana Life Sciences says foralumab shows promise in Alzheimer's treatmentFebruary 11, 2025 | proactiveinvestors.comTiziana announces TV interview with AD patient dosed with foralumabFebruary 11, 2025 | markets.businessinsider.comTiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s DiseaseFebruary 11, 2025 | markets.businessinsider.comTiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's DiseaseFebruary 11, 2025 | globenewswire.comShort Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Drops By 21.4%January 31, 2025 | marketbeat.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Growth in Short InterestJanuary 28, 2025 | marketbeat.com Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSA Media Mentions By Week TLSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TLSA News Sentiment▼0.000.57▲Average Medical News Sentiment TLSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TLSA Articles This Week▼01▲TLSA Articles Average Week Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XERS News Today CRON News Today REPL News Today VIR News Today SION News Today GYRE News Today PHAT News Today ANAB News Today IMTX News Today TRVI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TLSA) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLSA Stock Alerts